10th INTERNATIONAL CONFERENCE ON ALZHEIMER'S DRUG DISCOVERY

10th INTERNATIONAL CONFERENCE ON ALZHEIMER'S DRUG DISCOVERY

September 14-15, 2009 • Jersey City, NJ, USA (across from NYC on the Hudson)

Presented by the Alzheimer's Drug Discovery Foundation

• HOME

• PROGRAM

• SPEAKERS

• SCHOLARSHIPS

• REGISTRATION

• VENUE/ACCOMMODATIONS

• SPONSORSHIP/EXHIBIT

• SUPPORTERS

• CONTACT

COURSE PROGRAM

Sunday, September 13
5:00–7:00 pm		On-Site Pre-Registration
Monday, September 14
7:30 – 8:30am		Registration & Continental Breakfast
8:30 – 8:45		Welcome & Opening Remarks
		Howard Fillit, MD, Executive Director, Alzheimer's Drug Discovery Foundation read bio
8:45 – 9:15		Plenary: Bridging Neurocognitive Aging and Disease Modification: Targeting Functional Mechanisms of Impairment
		Michela Gallagher, PhD, Johns Hopkins University
I. Neuroprotection & Prevention Chair: Frank Longo, MD, PhD, Stanford University (confirmed)
9:15 – 9:20		Session Overview – Frank Longo, MD, PhD, Stanford University
9:20– 9:40		BDNF Small Molecule Mimetics for the Treatment of Alzheimer’s Disease
		Frank Longo, MD, PhD, Stanford University read bio
9:40– 9:50		Q&A
9:50-10:10		DHA for the Treatment of Alzheimer’s Disease
		Karin Yurko-Mauro, PhD, Martek Biosciences Corporation read bio
10:10-10:20		Q&A
10:20–10:40		BREAK
10:40– 11:00		Evaluation of PPAR-sparking thiozolidinediones as potential treatments for AD
		Jerry Colca, PhD, Metabolic Solutions Development Company read bio
11:00–11:10		Q&A
11:10–11:30		miRNAs in CNS Function and as Potential Therapeutics
		Asa Abeliovich, MD, PhD, Columbia University read bio
11:30-11:40		Q&A
11:40–12:00		Efficacy of herbal extract, tetramethylpyrazine, in Alzheimer's transgenic mice
		Zhiqun Tan, MD, PhD, UC Irvine read bio
12:00-12:10		Q&A
12:10–12:30		Disaggregation of Tau as a Therapeutic Approach to Tauopathies
		Karen Duff, PhD, Columbia University Medical Center read bio
12:30-12:40		Q&A
12:40–1:45		LUNCH
II. Anti-Amyloid & Protein Misfolding Chair: Michael Wolfe, PhD, Brigham and Women's Hospital
1:45– 1:50		Session Overview – Michael Wolfe, PhD
1:50– 2:10		Selective Amyloid-Lowering Agents
		Michael Wolfe, PhD, Brigham and Women’s Hospital read bio
2:10– 2:20		Q&A
2:20– 2:40		New Methods to Explore Marine Resources for Alzheimer’s Disease
		Philip Williams, PhD, University of Hawaii at Mahoa read bio
2:40– 2:50		Q&A
2:50– 3:10		Investigation of the Role of SEP in Controlling Cerebral Beta-Amyloid Pathology
		Robert Marr, PhD, Rosalind Franklin University of Medicine and Science read bio
3:10– 3:20		Q&A
3:20– 3:40		Interaction between Abeta and Fibrinogen: A New Therapeutic Target for Alzheimer's Disease
		Sidney Strickland, PhD, Rockefeller University read bio
3:40– 3:50		Q&A
3:50– 4:05		BREAK
4:05– 4:25		Targeted Hydrolysis of Beta-Amyloid with Engineered Antibody Fragments
		Michael Sierks, PhD, Arizona State University read bio
4:25– 4:35		Q&A
4:35– 4:55		Enhancing IDE-mediated Destruction of Abeta and other Amyloidogenic Peptides
		Walter Schmidt, PhD, University of Georgia read bio
4:55– 5:05		Q&A
5:05– 5:25		Betasynuclein Derived Peptide Sequences for Treatment of Alzheimer's Disease: Efficacy of a Peptidomimetic Compound in a Transgenic Mouse Model of Alzheimer's Disease
		Manfred Windisch, JSW Research read bio
5:25-5:35		Q&A
5:35-5:45		Closing Remarks
		Diana Shineman, PhD, Assistant Director of Scientific Programs, ADDF read bio
5:45–7:00		NETWORKING RECEPTION
Tuesday, September 15
8:15–9:00 am	Continental Breakfast
9:00–9:30	Plenary: TDP-43 as a New Target for Neurodegenerative Disease
	Virginia M.-Y. Lee, PhD, MBA, University of Pennsylvania read bio
III. Anti-Tangles & Frontotemporal Dementia Chair: Jeff Kuret, PhD, Ohio State University (confirmed)
9:30–9:35	Session Overview – Jeff Kuret, PhD, Ohio State University
9:35–9:55	Imaging Agents for Premortem Diagnosis and Staging of Tauopathies
	Jeff Kuret, PhD, Ohio State University read bio
9:55–10:05	Q&A
10:05–10:25	Hsp90 Inhibitors in Tauopathies: In vivo Pre-Clinical Development
	Gabriela Chiosis, PhD, Memorial Sloan-Kettering Cancer Center, New York read bio
10:25–10:35	Q&A
10:35–11:50	BREAK
10:50–11:10	Clearance of Pathological Tau Confomers
	Einar Sigurdsson, PhD, New York University read bio
11:10–11:20	Q&A
11:20–11:40	Novel Approaches for Targeting Tau Oligomers
	James Moe, PhD, MBA, Oligomerix, Inc.
11:40–11:50	Q&A
11:50–12:50	LUNCH
IV. Alternative Strategies: New Targets for AD Therapy Chair: Diana Shineman, PhD, Alzheimer’s Drug Discovery Foundation
12:50–12:55	Session Overview – Diana Shineman, PhD, ADDF
12:55–1:15	PDE9: A New Target for Alzheimer’s Disease
	Rebecca M. Evans, MD, Pfizer
1:15–1:25	Q&A
1:25–1:45	Screening for Small Molecule Agonists of Phosphatidylinositol 4-kinase
	Tae-Wan Kim, PhD, Columbia University Medical Center read bio
1:45–1:55	Q&A
1:55–2:15	Peptidomimetics for Elimination of Cofilin Pathology in Alzheimer’s Disease
	James Bamburg, PhD, Colorado State University read bio
2:15–2:25	Q&A
2:25–2:45	Treatment of Alzheimer’s Disease with mGluR5 Inhibitor
	James Malter, MD, University of Wisconsin at Madison read bio
2:45–2:55	Q&A
2:55-3:10	BREAK
3:10–3:30	Expedient and Versatile Methods for the Production of Investigational Drugs for SPECT and PET Imaging of AD
	Graham Jones, PhD, Northeastern University read bio
3:30-3:40	Q&A
3:40–4:00	Novel Approach to Enhance Cognition through the Dopamine D1 Receptor System by Inhibition of PDE1B
	Lawrence P. Wennogle, PhD, Intra-Cellular Therapies, Inc. read bio
4:00-4:10	Q&A
4:10–4:20	Closing Remarks
	Howard Fillit, MD, Executive Director, Alzheimer's Drug Discovery Foundation read bio

TOP

IMPORTANT DATES

August 21, 2009 - Deadline for Discounted Room Reservation at the Conference Venue >>>

August 21, 2009 - NEW Early Bird Registration Deadline >>>